A Pharmacokinetic and Phase II Study of Pertuzumab in Combination With Trastuzumab And Eribulin (Halaven) in Patients With Advanced HER2-Positive Breast Cancer

Trial Profile

A Pharmacokinetic and Phase II Study of Pertuzumab in Combination With Trastuzumab And Eribulin (Halaven) in Patients With Advanced HER2-Positive Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Eribulin (Primary) ; Pertuzumab; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2016 Status changed from discontinued to completed.
    • 29 Jul 2015 Status changed from recruiting to suspended as per University Hospital Medical Information Network - Japan record.
    • 10 Jan 2014 Status changed from not yet recruiting to recruiting according to UMIN record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top